GSK claims Amgen v Sanofi decision “threatens” innovation

GlaxoSmithKline (GSK) has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circ rejects Sanofi’s bid to resurrect Lantus patents

4 January 2022 The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.

Generics

GSK responds to Teva’s ‘skinny’ label rehearing petition

9 December 2021 Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne has added its response to the petition to rehear the case yet again.

Americas

Fed Circ invaded jury’s role in Repatha case, says Amgen

25 November 2021 Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

GSK claims Amgen v Sanofi decision “threatens” innovation

More on this story

Editor's picks

Editor's picks

More features